"The U.S. health care system is broken, and it's time to fix it" seemed to be the mantra at Tuesday's Senate Health, Education, Labor and Pensions (HELP) Committee hearing on a bipartisan bill aimed at curbing health care costs. The bill, which the committee plans to mark up next week, contains nearly three dozen provisions addressing insurance, provider and prescription drug costs and practices. Read More
Less than a month after changing its name from Flx Bio Inc., the newly minted Rapt Therapeutics Inc. has extended its series C financing by securing an additional $37 million. Read More
DUBLIN – Imcyse SA raised €28 million (US$31.4 million) in a series B round and several million more in grant and debt funding to progress its Imotope therapeutic vaccine technology for inducing tolerance to autoantigens implicated in chronic autoimmune disease. Read More
The digital therapeutics market is witnessing considerable growth globally thanks to the confluence of the development of new technologies, the increasing prevalence of chronic diseases and lifestyle-associated diseases and an aging population. Read More
Last week at the Goldman Sachs Healthcare Conference in Rancho Palos Verdes, Calif., Sarepta Therapeutics Inc. CEO Douglas Ingram noted that "more than a kid a day dies" from Duchenne muscular dystrophy (DMD) in the U.S., adding that officials at his Cambridge, Mass.-based firm "feel an enormous obligation to move heaven and earth to get this [gene] therapy to the community if it's possible" and quickly. Read More
HONG KONG – China has approved its third homegrown PD-1 drug in merely six months, with a nod for camrelizumab, developed by pharma R&D giant Jiangsu Hengrui Medicine Co. Ltd., as a third-line treatment for recurrent or refractory classical Hodgkin lymphoma. Read More
F-star Therapeutics Ltd., of Cambridge, U.K., said it established its U.S. operational base in Cambridge, Mass. Research operations will continue at the company's U.K. site while the U.S. office leads the company's financial, clinical and regulatory activities. Read More
Rockwell Medical Inc., of Wixom, Mich., said it priced its underwritten public offering of 5.83 million shares at $3 each. The underwriters have been granted a 30-day option to purchase up to an additional 875,000 shares of its common stock at the public offering price. Read More
